Subclinical hypothyroidism management (persistently elevated TSH with normal free T4)
Subclinical hypothyroidism is managed with confirmation of persistence, assessment for autoimmune thyroid disease, and symptom and risk stratification before considering levothyroxine therapy. [1] For adults with confirmed subclinical hypothyroidism, levothyroxine treatment is generally considered based on the degree of TSH elevation and clinical context. [1]
Diagnostic confirmation and initial evaluation
Persistently elevated TSH with normal free T4 requires repeat testing to confirm persistence. [2] Thyroid peroxidase antibodies (TPOAbs) should be considered for adults with TSH levels above the reference range. [1] TPOAbs testing should not be routinely repeated. [1] Autoimmune thyroid disease features and thyroid disease history should be incorporated into decision-making about treatment initiation. [1]
Medication selection algorithm
Levothyroxine is the treatment of choice when therapy is started for subclinical hypothyroidism. [2] Levothyroxine should be withheld as routine therapy for most adults with TSH elevations below 10 mIU/L in the absence of features suggesting underlying thyroid disease or clinical risk. [1]
Treatment initiation thresholds
Levothyroxine should be considered for adults with subclinical hypothyroidism who have a TSH of 10 mIU/L or higher on 2 separate occasions spaced 3 months apart. [1] A 6-month trial of levothyroxine should be considered for adults under 65 years with TSH above the reference range but below 10 mIU/L on 2 separate occasions spaced 3 months apart when symptoms of hypothyroidism are present. [1] Reassessment should occur after initiation in the presence of symptoms. [1]
Monotherapy vs combination therapy
Levothyroxine monotherapy is recommended when treating subclinical hypothyroidism. [2] Liothyronine or combination T4/T3 therapy is not recommended as routine management for subclinical hypothyroidism. [2]
Important clarifications and nuances
The decision to start treatment for subclinical hypothyroidism should incorporate features suggestive of underlying thyroid disease. [1] Symptoms that persist when TSH returns to the reference range after therapy should prompt consideration of stopping levothyroxine. [1]
Monitoring strategy when not treated
For adults with untreated subclinical hypothyroidism, TSH and free T4 should be measured once yearly if features suggesting underlying thyroid disease are present. [1] For adults without features suggesting underlying thyroid disease, TSH and free T4 should be measured once every 2 to 3 years. [1]
Common pitfalls to avoid
Treatment initiation should not be based on a single abnormal TSH measurement because persistence should be confirmed with repeat testing. [1] TPOAbs should not be re-measured routinely, because repeat testing is not recommended. [1] Levo-thyroxine treatment should not be continued when symptoms persist despite biochemical normalization (TSH in the reference range), since stopping should be considered. [1]
Targets or goals of therapy
Treatment aims should focus on normalization of TSH into the reference range during levothyroxine therapy. [1]
Sources: [1] NICE NG145, section 1.5.3–1.5.7 and 1.5.1. [1] [2] 2013 European Thyroid Association guideline review article describing confirmation and timing (repeat TSH/FT4 and TPOAbs after 2–3 months) and levothyroxine as treatment of choice. [2]